NLRP3 and type 2 diabetes mellitus: The NLRP3 inflammasome has become an attractive therapeutic target because growing evidence has shown that its inappropriate activation is involved in the pathogenesis of many complex diseases, such as Alzheimer’s disease, type 2 diabetes, and gout [5,6].